Foghorn Therapeutics Inc. (FHTX) closed the last trading session at $6.20, gaining 2.7% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $13.75 indicates a 121.8% upside potential. The mean estimate comprises four short-term price targets with a standard deviation of $5.91. While the lowest estimate of $6 indicates a 3.2% decline from the current price level, the most optimistic ana ...

Foghorn Therapeutics Inc. (FHTX) came out with a quarterly loss of $0.45 per share versus the Zacks Consensus Estimate of a loss of $0.60. This compares to loss of $0.70 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 25%. A quarter ago, it was expected that this company would post a loss of $0.55 per share when it actually produced a loss of $0.59, delivering a surprise of -7.27%. Over the last four quarters, the company has ...

Former White House Top Health Security Official to Lead Flagship's Preemptive Health and Medicine Initiative CAMBRIDGE, Mass., Aug. 6, 2024 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today announced that globally distinguished healthcare expert, entrepreneur, and public policy leader Raj Panjabi, M.D., MPH, will join Flagship as Senior Partner. Dr. Panjabi will lead Flagship's Preemptive Health and Medicine Initiative (PH&M), which is pioneering a new field to protect, maintain ...

The Abiologics platform leverages cutting-edge generative AI and high throughput chemical protein synthesis to create Synteins™, a new class of programmable medicines that aims to redefine what therapeutics can achieve for patients CAMBRIDGE, Mass., July 23, 2024 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today unveiled Abiologics, a company reimagining biologics with the creation of a new class of supranatural and programmable medicines, called Synteins™. Synteins are computat ...

Record Year with Key Partnerships, Global Expansion and Expanded Top Talent "Over the past six years, Flagship has also pioneered AI-enabled platforms that transform drug discovery, speed up the drug development process and gain new insights into human health and sustainability," Afeyan added. "By leveraging the power and potential of generative AI, we're embracing a future in which companies are created and expanded in ways we have not previously experienced, with the prospect for unprecedented impact." Pa ...

Core Insights - Foghorn Therapeutics Inc. is a clinical-stage biotechnology company focused on developing a new class of medicines that correct abnormal gene expression to treat serious diseases, with an initial emphasis on oncology [1][3] - The company utilizes its proprietary Gene Traffic Control® platform to identify and validate drug targets within the chromatin regulatory system, aiming to transform the treatment landscape for various diseases [3] Conference Participation - Foghorn Therapeutics will present at the Jefferies Global Healthcare Conference on June 5, 2024, at 3:30 p.m. ET, with CEO Adrian Gottschalk as the presenter [2] - The company will also participate in one-on-one meetings during the Jefferies conference [2] - Additionally, Foghorn will present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024, at 3:20 p.m. ET, again featuring CEO Adrian Gottschalk [2] - One-on-one meetings will also be held during the Goldman Sachs conference [2] Company Overview - Foghorn Therapeutics is engaged in discovering and developing medicines that target genetically determined dependencies within the chromatin regulatory system [3] - The company is developing multiple product candidates specifically in the oncology sector [3] - More information about the company can be found on its website and social media platforms [3]

Positions company to further leverage strength of platform and advance programs through multiple data readouts and clinical value inflection points Strengthens balance sheet with cash, cash equivalents and short-term investments of $310 million and extends cash runway into 2027 CAMBRIDGE, Mass., May 22, 2024 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expressi ...

Positions company to further leverage strength of platform and advance programs through multiple data readouts and clinical value inflection points Strengthens balance sheet with cash, cash equivalents and short-term investments of $310 million and extends cash runway into 2027 CAMBRIDGE, Mass., May 22, 2024 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expressi ...

Foghorn Therapeutics Inc. (FHTX) came out with a quarterly loss of $0.59 per share versus the Zacks Consensus Estimate of a loss of $0.55. This compares to loss of $0.73 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -7.27%. A quarter ago, it was expected that this company would post a loss of $0.79 per share when it actually produced a loss of $0.57, delivering a surprise of 27.85%.Over the last four quarters, the company ha ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q _____________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________________ to __________________ Commission File Number: 001-39634 ______________________ Foghorn Therapeutics Inc ...